Literature DB >> 20232161

A clinicopathologic analysis of peritoneal metastases of colorectal and appendiceal origin.

Sjoerd C Bruin1, Victor J Verwaal, Andrew Vincent, Laura J van't Veer, Marie-Louise F van Velthuysen.   

Abstract

OBJECTIVE: To predict clinical outcome by classification of peritoneal metastases (PM) of colorectal or appendiceal origin.
BACKGROUND: This study investigates whether standardized histological classification can predict outcome for PM of colorectal or appendiceal origin treated with cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
METHODS: Histology of PM (n = 269) was evaluated by analysis of mitotic activity, atypia, cellularity, and mucinous component. For overall survival (OS) and disease-free survival (DFS) Cox proportional-hazard models were constructed. Covariates included tumor, patient, and treatment characteristics.
RESULTS: PM could be categorized into four groups: low-grade, well-differentiated mucinous tumor (DPAM); intermediated-grade mucinous carcinoma (PMCA-i); high-grade mucinous carcinoma (PMCA); and high-grade nonmucinous carcinoma (PCA). Multivariate analysis showed that histological classification, gender, number of segments affected, completeness of cytoreduction, and HIPEC as primary treatment were significant related to OS and DFS. The 5-year OS was 64% in the DPAM group, 36% in the PMCA group, and 24% in the PCA group. Of PM originating from an appendix tumor, 29% were of non-DPAM type. Of primary colorectal tumors, 37% resulted in mucinous PM, and another 26% of PM of colorectal origin had partly mucinous histology.
CONCLUSION: Histology is a significant predictive factor of OS and DFS in PM treated with surgical cytoreduction and HIPEC. Low-grade PM (DPAM) should be regarded as a separate entity because of its clearly different clinical course. High-grade mucinous PM has significant better prognosis than nonmucinous PM and should thus be distinguished.

Entities:  

Mesh:

Year:  2010        PMID: 20232161     DOI: 10.1245/s10434-010-0984-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  10 in total

1.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience.

Authors:  Ayman Zaki Azzam; Zyad Adil Alyahya; Ahmed Abbas Al Wusaibie; Tarek Mahmoud Amin
Journal:  Indian J Gastroenterol       Date:  2017-11-29

Review 2.  Pseudomyxoma peritonei as an intractable disease and its preoperative assessment to help improve prognosis after surgery: A review of the literature.

Authors:  Yuesi Zhong; Meihai Deng; Ruiyun Xu; Norihiro Kokudo; Wei Tang
Journal:  Intractable Rare Dis Res       Date:  2012-08

3.  Impact of a modified peritoneal cancer index using FDG-PET/CT (PET-PCI) in predicting tumor grade and progression-free survival in patients with pseudomyxoma peritonei.

Authors:  Masatoshi Hotta; Ryogo Minamimoto; Yoshimasa Gohda; Toru Igari; Hideaki Yano
Journal:  Eur Radiol       Date:  2019-03-14       Impact factor: 5.315

4.  Outcome of patients with aggressive pseudomyxoma peritonei treated by cytoreductive surgery and intraperitoneal chemotherapy.

Authors:  Alvaro Arjona-Sanchez; Francisco Cristobal Muñoz-Casares; Angela Casado-Adam; Juan Manuel Sánchez-Hidalgo; Maria Dolores Ayllon Teran; Rafael Orti-Rodriguez; Ana Cristina Padial-Aguado; Javier Medina-Fernández; Rosa Ortega-Salas; Gema Pulido-Cortijo; Auxiliadora Gómez-España; Sebastián Rufián-Peña
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

Review 5.  The Role of Hyperthermic Intraperitoneal Chemotherapy for Non-colorectal Peritoneal Surface Malignancies.

Authors:  Mackenzie C Morris; Jordan M Cloyd; John Hays; Sameer H Patel
Journal:  J Gastrointest Surg       Date:  2020-08-17       Impact factor: 3.452

6.  Pseudomyxoma peritonei of 92 Chinese patients: clinical characteristics, pathological classification and prognostic factors.

Authors:  Ai-Tao Guo; Yan-Mi Li; Li-Xin Wei
Journal:  World J Gastroenterol       Date:  2012-06-28       Impact factor: 5.742

7.  Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis.

Authors:  Eric Marcotte; Pierre Dubé; Pierre Drolet; Andrew Mitchell; Suzanne Frenette; Guy Leblanc; Yves E Leclerc; Lucas Sideris
Journal:  World J Surg Oncol       Date:  2014-11-07       Impact factor: 2.754

8.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in ovarian and gastrointestinal peritoneal carcinomatosis: results from a 7-year experience.

Authors:  Giulia Montori; Federico Coccolini; Paola Fugazzola; Marco Ceresoli; Matteo Tomasoni; Carolina Rubicondo; Stefano Raimondo; Domenico Pinelli; Michele Colledan; Luigi Frigerio; Luca Ansaloni
Journal:  J Gastrointest Oncol       Date:  2018-04

9.  A contemporary analysis of morbidity and outcomes in cytoreduction/hyperthermic intraperitoneal chemoperfusion.

Authors:  Michelle Haslinger; Valerie Francescutti; Kristopher Attwood; Judith Andrea McCart; Marwan Fakih; John M Kane; Joseph J Skitzki
Journal:  Cancer Med       Date:  2013-04-16       Impact factor: 4.452

10.  Stratification of outcomes for mucinous appendiceal adenocarcinoma with peritoneal metastasis by histological grade.

Authors:  Travis Edward Grotz; Richard E Royal; Paul F Mansfield; Michael James Overman; Gary N Mann; Kristen Ashlee Robinson; Karen A Beaty; Safiea Rafeeq; Auerlio Matamoros; Michelle W Taggart; Keith Francis Fournier
Journal:  World J Gastrointest Oncol       Date:  2017-09-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.